|Artificial Intelligence-Powered Sugar.IQ(TM) Diabetes Management App Developed by Medtronic and IBM Watson Health Now Commercially Available|
(GLOBE NEWSWIRE via COMTEX) --Real-World Experience Data on Sugar.IQ App Use Presented
DUBLIN AND CAMBRIDGE - June 22, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, services and solutions, and its strategic technology partner, IBM (NYSE:IBM) Watson Health, today announced commercial availability of the Sugar.IQ(TM) smart diabetes assistant, a first-of-its-kind intelligent app designed to simplify and improve daily diabetes management.
Approximately 30.3 million Americans have been diagnosed with diabetes, with 1.5 million new cases being diagnosed every year.1 More than 6 million of those impacted use insulin to manage their diabetes.2 People with diabetes face many daily challenges - managing their condition, understanding medical advice, knowing what to eat and when, the impact of food and activity on sugar levels, and trying to avoid critical glycemic events. The groundbreaking Sugar.IQ smart diabetes assistant leverages artificial intelligence (AI) and analytic technologies from IBM Watson Health to continually analyze how an individual's glucose level responds to their food intake, insulin dosages, daily routines, and other factors, such as information provided by the app user.
For example, are certain foods worsening the patient's glucose control? Are there particular days or times where a person's glucose goes high or low? With Sugar.IQ, people with diabetes can uncover patterns that affect their glucose levels which can help them make small adjustments throughout the day to help stay on track.
Medtronic and IBM Watson Health leveraged their combined expertise in diabetes, AI and analytics to develop the Sugar.IQ diabetes assistant. The Sugar.IQ assistant reveals patterns that may be hard to see so that someone with diabetes gains meaningful, personalized insights. These insights show how lifestyle choices, medications, and multiple daily injections impact diabetes management and the time spent with glucose in the target range. The app uses AI and advanced analytics to give users a full picture of their current levels and provides insights and individualized guidance in understanding and managing daily diabetes management decisions, so that people on multiple daily insulin injections have more freedom to enjoy life.
In data presented at the 78th Annual American Diabetes Association (ADA) Scientific Sessions on June 22, 2018, people who used the Sugar.IQ app spent 36 minutes more per day in healthy glucose range than they did before using the app. This included 30 minutes less time in hyperglycemia (>180 mg/dL) and 6 minutes less time in hypoglycemia (<70 mg/dL).3 This represents more than 9 additional days in a year that a person with diabetes is spending in a healthy glucose range.
According to Michelle Shaw, a Medtronic employee and registered nurse (RN) who has been using the Sugar.IQ app for 4 weeks through an employee preview program, "Sugar.IQ has given me insights that I could never have uncovered on my own - even with 30 years of diabetes experience. It's been eye opening and fun to gain new insights into my diabetes without additional burden."
The Sugar.IQ app is available to users of the Medtronic Guardian(TM) Connect system, the first smart standalone CGM system4 designed to empower people with diabetes using multiple daily injections (MDI) with actionable tools to help them get ahead of high and low glucose levels - not just react to them. With customizable predictive alerts up to 60 minutes before a high or low, and the Sugar.IQ assistant, Guardian Connect CGM provides people with more tools to stay in range than any other CGM system.5
The Sugar.IQ app is available for iOS-based mobile devices in the U.S.
Devices alone cannot transform diabetes care. The combination of patient engagement, technologies, big data and analytics, informatics and world-class patient management are all required to drive effective results in diabetes care. By leveraging Medtronic devices and care management offerings-including therapies and coaching-and with IBM Watson Health's powerful analytic and AI capabilities, Medtronic can leverage data-driven insights to help people with diabetes and their caregivers.
About IBM Watson Health
Watson Health is a business unit of IBM that is dedicated to the development and implementation of AI and data-driven technologies to advance health. Watson Health technologies are tackling a wide range of the world's biggest healthcare challenges including cancer, diabetes, drug discovery and more. Learn more at ibm.com/watson/health.
About the Diabetes Group at Medtronic (www.medtronicdiabetes.com)
Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care and improving outcomes, so people living with diabetes can enjoy greater freedom and better health.
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 86,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
1 American Diabetes Association, Overall Numbers, Diabetes and Prediabetes, March 22, 2018
2 American Diabetes Association, Fast Facts: Data and Statistics about Diabetes, December 2015
3 Usage of Sugar.IQ app was analyzed based on data from 256 randomly offered real-world MiniMed 530G users from April to August 2017
4 Smart CGM predicts future high and low sensor glucose events and provides access to additional algorithms and insights that can inform users of clinically relevant glucose patterns
5 Decision-making around insulin dosages should always follow the guidance of a patient's healthcare professional.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medtronic plc via Globenewswire